Miochol-E (Acetylcholine Chloride)

Acetylcholine Chloride, the active ingredient in Miochol‑E, is a direct‑acting cholinergic agonist presented as an ophthalmic solution for intraocular use. It induces rapid pupil constriction (miosis) during intraocular surgery and facilitates diagnostic testing of ocular function in adult patients.

GNH USA supplies Miochol‑E as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide, ensuring consistent quality through robust quality management systems.

Miochol‑E, a direct‑acting cholinergic agonist, is used in ophthalmic procedures that require pupil constriction.

Intraocular surgery: induces miosis to improve surgical access and reduce intra‑operative complications. Diagnostic pupillary testing: facilitates assessment of pupillary reflexes and accommodation. Anterior segment procedures: aids in controlling iris movement during laser or microsurgical interventions.

Topical ocular administration of Miochol‑E can produce a range of ocular and systemic reactions.

Common Side Effects: - Transient blurred vision: temporary loss of visual clarity after instillation. - Eye irritation: mild burning or stinging sensation. - Conjunctival hyperemia: redness of the eye. - Mild headache: occasional headache due to cholinergic stimulation.

Serious or Rare Side Effects: - Acute angle‑closure glaucoma: rapid increase in intra‑ocular pressure in susceptible eyes. - Severe ocular pain: persistent pain requiring medical attention. - Systemic cholinergic toxicity: bradycardia, hypotension, bronchospasm in rare systemic absorption.

Prior assessment and careful monitoring are essential when using Miochol‑E. - Assess anterior chamber angle: avoid use in patients with narrow‑angle glaucoma. - Monitor intra‑ocular pressure: check IOP before and after administration in at‑risk individuals. - Avoid in hypersensitivity: discontinue if allergic reaction occurs. - Use with caution in patients on systemic cholinergic drugs: potential additive effects. - Pregnancy and lactation: safety not established; weigh benefits against risks. - Store at room temperature: keep in original container, protect from light and moisture.

Miochol‑E may interact with other ocular or systemic agents that influence cholinergic pathways.

Major Interactions (Avoid): - Systemic anticholinergics (e.g., atropine): antagonize ocular effect, reducing miosis. - Beta‑blocker eye drops: may exacerbate intra‑ocular pressure changes.

Moderate Interactions (Monitor Closely): - Topical miotics (e.g., pilocarpine): additive cholinergic effect, increase risk of prolonged miosis. - Systemic cholinesterase inhibitors (e.g., donepezil): may enhance cholinergic response. - Inhaled muscarinic antagonists (e.g., ipratropium): potential reduced efficacy of Miochol‑E.